[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592135":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":31,"locations":41,"responsibleParty":64,"collaborators":66,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":12,"eligibilityCriteria":76,"healthyVolunteers":72,"sex":77,"minAge":78,"maxAge":12,"enrollmentInfo":79,"targetDuration":12,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":44,"whyStopped":12,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"UNC Lineberger Comprehensive Cancer Center","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard of Care patients","NO_INTERVENTION","Clinical pharmacists will follow their specific standards of procedure when educating patients on oral anticancer agents. No longitudinal following or tailored patient support will be provided. This group of participants will serve as the control group of the study.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Intervention participants","EXPERIMENTAL","Participants enrolled in this adherence program will have individualized counseling sessions with their clinical pharmacists regarding their oral anticancer agent. Participants will be followed longitudinally and will receive tailored support.",[18],"Behavioral: Multilevel Adherence Intervention",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"BEHAVIORAL","Multilevel Adherence Intervention","Participants enrolled in this adherence program will have individualized counseling sessions with their clinical pharmacists regarding their oral anticancer agent based on their risk-stratified monitoring category. Participants will be followed longitudinally and will receive tailored support.",[14],[26],"Multicomponent Adherence Intervention",[28],{"name":29,"affiliation":5,"role":30},"Benyam Muluneh, PharmD","PRINCIPAL_INVESTIGATOR",[32,37],{"name":33,"role":34,"phone":35,"phoneExt":12,"email":36},"Solomon Ayehu, MD","CONTACT","9196722032","solsay@unc.edu",{"name":38,"role":34,"phone":39,"phoneExt":12,"email":40},"Bethel Belayneh","7039154836","bdbelay@ad.unc.edu",[42],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"UNC Chapel Hill","RECRUITING","Chapel Hill","North Carolina","27516","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-79.05584,35.9132,{"lat":54,"lon":53},[57,61,62],{"name":58,"role":34,"phone":59,"phoneExt":12,"email":60},"Benyam Muluneh","919-962-0070","bmuluneh@unch.unc.edu",{"name":38,"role":34,"phone":12,"phoneExt":12,"email":40},{"name":63,"role":30,"phone":12,"phoneExt":12,"email":12},"Benyam Muluneh, Pharm.D.",{"type":65,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR",[67],{"name":68,"class":69},"National Cancer Institute (NCI)","NIH","100592135","implementation-of-an-oral-chemotherapy-adherence-intervention-100592135",false,"NCT06989489","Implementation of an Oral Chemotherapy Adherence Intervention","Design and Implementation of a Social Cognitive Theory-based Medication Adherence Intervention","Inclusion Criteria:\n\n* Adult (age ≥21 years-old) patients\n* Diagnosed with a solid or hematologic malignancy\n* Monotherapy on oral anticancer agent on treatment for at least 6 months\n\nExclusion criteria:\n\n* Patients on time-limited or intermittent therapy (non-continuous)\n* Patients on comfort (end-of-life) care\n* Patients enrolled on hospice","ALL","21 Years",{"count":80,"type":81},160,"ESTIMATED","INTERVENTIONAL",[84],"NA","The goal of this study is to evaluate the effectiveness and usability of a newly developed oral anticancer agent adherence program implemented across 6 cancer clinics (two academic, two urban, and two rural). The study will include 160 adult participants with either solid tumors or hematologic malignancies who have been taking oral anticancer agents for at least six months.\n\nThis study will have two groups of participants, a pre- and post-implementation group. In the pre-implementation of the program group, investigators will administer a survey to the 80 participants and gather information about their medication prior to their enrollment of the program. Similarly, 80 participants who have been enrolled into this program for at least 6 months will serve as the post-implementation group. These patients will be administered the same survey. The results from both groups will be analyzed to see how effective the medication adherence program is.",[87,88],"Solid Tumor","Hematologic Malignancy",[90,91,92],"oral anticancer agent","oral chemotherapy","adherence","2026-07-06",{"date":95,"type":96},"2026-07-08","ACTUAL",{"date":98,"type":96},"2025-05-28",{"date":100,"type":81},"2028-08-30",{"name":5,"class":6},1]